Massive jury award against J&J highlights risks of its legal strategy

A jury award that hit Johnson & Johnson with $8 billion in punitive damages for a case involving its anti-psychotic drug Risperdal highlights the risks of the drugmaker's all-or-nothing legal strategy, several legal experts told Reuters on Wednesday.